BeiGene, Ltd. (BGNE) News
Filter BGNE News Items
BGNE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
BGNE News Highlights
- BGNE's 30 day story count now stands at 16.
- Over the past 25 days, the trend for BGNE's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
- The most mentioned tickers in articles about BGNE are DRUG, SNDA and WM.
Latest BGNE News From Around the Web
Below are the latest news stories about BeiGene Ltd that investors may wish to consider to help them evaluate BGNE as an investment opportunity.
BeiGene''s Brukinsa Applications Under FDA, European Review For LeukemiaThe European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd''s (NASDAQ: BGNE ) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its |
BeiGene''s Brukinsa gets FDA review for expanded use in blood cancer subtypeThe U.S. Food and Drug Administration ((FDA)) accepted BeiGene''s (BGNE) application seeking approval of Brukinsa (zanubrutinib) to treat adult patients with chronic lymphocytic |
BeiGene's Brukinsa Applications Under FDA, European Review For LeukemiaThe European Medicines Agency (EMA) has accepted for review two new indication applications for BeiGene Ltd's (NASDAQ: BGNE) Brukinsa (zanubrutinib) for chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL). In November 2021, Brukinsa received its first approval in the European Union (EU) for Waldenström's macroglobulinemia (WM), who have received at least one prior therapy or for the first-line treatment of patients unsuitable for chemo-immunotherapy. Additionally, the FDA has als |
BeiGene Announces European Medicines Agency Acceptance of Applications for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia and Marginal Zone LymphomaBASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 22, 2022--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that the European Medicines Agency (EMA) has accepted for review two new indication applications for its BTK inhibitor BRUKINSA® (zanubrutinib) for the treatment of patients with chronic lymphocyt |
BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic LeukemiaCAMBRIDGE, Mass. and BEIJING, February 22, 2022--BeiGene Announces U.S. FDA Acceptance of Supplemental New Drug Application for BRUKINSA (zanubrutinib) in Chronic Lymphocytic Leukemia |
BeiGene''s Brukinsa for blood cancer subtype gets approval in SwitzerlandBeiGene''s (BGNE) Brukinsa (zanubrutinib) was approved by Swissmedic to treat adult patients with Waldenström’s macroglobulinemia ((WM)) who have received at least one prior line of… |
BeiGene Announces Approval for BRUKINSA (zanubrutinib) by Swissmedic for Treatment of Adult Patients with Waldenström’s MacroglobulinemiaBASEL, Switzerland & CAMBRIDGE, Mass. & BEIJING, February 17, 2022--BeiGene announces approval for BRUKINSA (zanubrutinib) by Swissmedic for the treatment of adult patients with Waldenström’s Macroglobulinemia |
BeiGene to Present at the Guggenheim Healthcare Talks - 2022 Oncology ConferenceCAMBRIDGE, Mass. & BEIJING, February 08, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global science-driven biotechnology company, today announced that the Company will participate in the Guggenheim Healthcare Talks, 2022 Oncology Conference on Thursday, February 10, 2022 at 9:00 a.m. ET. |
Drs. Margaret Dugan and Alessandro Riva Appointed to BeiGene Board of DirectorsCAMBRIDGE, Mass. & BEIJING, February 01, 2022--BeiGene announces the appointment of Margaret Dugan, M.D., and Alessandro Riva, M.D., to its Board of Directors. |
BeiGene''s Brukinsa application accepted in China for chronic lymphocytic leukemiaBeiGene (BGNE) announces its supplemental new drug application (sNDA) for BTK inhibitor BRUKINSA (zanubrutinib) has accepted by China National Medical Products Administration |